The Lymphomas Conference 3rd edition

Lymphoid malignancies represent one of the most biologically heterogeneous and therapeutically dynamic areas in modern hematology. Over the last decade, major advances in genomics, tumor microenvironment characterization, immune biology, and translational research have profoundly reshaped the classification, prognosis, and treatment of lymphomas. At the same time, the rapid expansion of novel therapeutic strategies—including targeted agents, antibody–drug conjugates, bispecific antibodies, and cellular therapies—has introduced unprecedented opportunities, but also significant clinical and strategic challenges. The Lymphomas Conference – 3rd Edition is conceived as an international, high-level scientific forum aimed at integrating biological insights with clinical decision-making, fostering a comprehensive and forward-looking discussion on both common and rare lymphoid malignancies. The meeting brings together leading basic scientists, translational researchers, and clinicians to critically analyze how molecular biology, genetics, epigenetics, immune interactions, and artificial intelligence are redefining disease understanding and therapeutic paradigms.

A central focus of the conference is Di use Large B-Cell Lymphoma (DLBCL), used as a model to illustrate the transition from biologically driven classification to precision treatment strategies, including optimal sequencing of immunochemotherapy, bispecific antibodies, CAR T-cell therapies, and emerging cellular platforms. Similar integrative approaches are extended to Hodgkin lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, Waldenström macroglobulinemia, chronic lymphocytic leukemia, and special lymphoma entities, addressing both frontline and relapsed/refractory settings. Special attention is devoted to unmet clinical needs, such as the management of elderly and frail patients, high-grade and transformed lymphomas, resistance mechanisms, minimal residual disease monitoring through circulating tumor DNA, and the evolving role of allogeneic transplantation in the era of immune and cellular therapies. Through interactive sessions, expert panels, and multidisciplinary discussions, the conference aims to:

• Bridge the gap between biological discovery and clinical practice;
• Promote critical evaluation of emerging therapies and treatment algorithms;
• Encourage rational sequencing and personalization of care;
• Stimulate collaboration among international experts across disciplines.

Ultimately, The Lymphomas Conference – 3rd Edition seeks to provide participants with a clear, evidence-based, and futureoriented framework to improve outcomes and quality of care for patients with lymphoid malignancies in an increasingly complex therapeutic landscape.

CREDITI ECM: Tale evento è accreditato e la partecipazione darà diritto all'acquisizione di 9,1 ECM per Medico Chirurgo e Farmacista. Obiettivo formativo nr. 3

ISCRIZIONE:

1. Download the “PROEVENTI” app on your smartphone.
2. Login or create a new account.
3. Enter the event pin: LYMPHOMAS26.
4. You are now on the event page, click on “REGISTRATION” at the top.

RESPONSABILI SCIENTIFICI: Dr. Gerardo MusuracaDr. Nicola Normanno

Gratuito previo iscrizione.